
HRV Pharma’s ₹150 Crore Bet Signals India’s Shift Toward Complex Pharma
Hyderabad-based HRV Pharma is committing approximately ₹150 crore to expand its capabilities in synthetic peptides and high-potency oncology APIs—two specialised segments where manufacturing capacity and regulatory expertise are becoming increasingly














































